Clinical trial
Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)
NCT00440297 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00440297 |
|---|---|
| Title | Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060) |
| Official title | A Study in Renal Predialysis and Dialysis Patients of the Safety, Tolerability, and Immunogenicity of Recombinant Hepatitis B Vaccine Manufactured With a Modified Process |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B Virus Infection |
| Intervention type | Biological |
| Interventions | Comparator: modified process hepatitis B vaccine, Comparator: ENGERIX-B™ |
| Enrollment | 277 |
| Start date | Dec 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Feb 27, 2007 |
| Last update posted | Apr 13, 2017 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: